Nouscom SRL
Nouscom is a private oncology company developing next-generation immunotherapies, focusing on engineered viral vectored vaccines for cancer treatment. Founded in 2015, it aims to generate safe, innovative, and potent cancer immunotherapies that selectively eliminate tumor cells. The company harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators, utilizing proprietary platform technologies. With offices and facilities in Basel, Switzerland, and Rome, Italy, Nouscom is advancing clinical trials and innovative vaccine platforms, including off-the-shelf neoantigen vaccines and personalized immunotherapies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Off-the-shelf shared frameshift neoantigen vaccine for MSI/dMMR tumors
Therapeutic vaccine concept comprising a repertoire of shared frameshift-derived neoantigens encoded in viral vectors and intended for use without patient-specific neoantigen selection; developed to target tumors with microsatellite instability/mismatch repair deficiency and evaluated in combination with checkpoint blockade.
Personalized neoantigen viral-vectored vaccine program
Personalized vaccine approach that selects patient-specific neoantigens from tumor mutanomes using computational prioritization and manufactures individualized clinical-grade viral-vectored vaccines for each patient.
Oncolytic virus discovery platform armed with immunomodulators
Discovery-stage oncolytic virus program designed for targeted tumor infection and delivery of immunomodulatory payloads to stimulate anti-tumor immunity.
Off-the-shelf shared frameshift neoantigen vaccine for MSI/dMMR tumors
Therapeutic vaccine concept comprising a repertoire of shared frameshift-derived neoantigens encoded in viral vectors and intended for use without patient-specific neoantigen selection; developed to target tumors with microsatellite instability/mismatch repair deficiency and evaluated in combination with checkpoint blockade.
Personalized neoantigen viral-vectored vaccine program
Personalized vaccine approach that selects patient-specific neoantigens from tumor mutanomes using computational prioritization and manufactures individualized clinical-grade viral-vectored vaccines for each patient.
Oncolytic virus discovery platform armed with immunomodulators
Discovery-stage oncolytic virus program designed for targeted tumor infection and delivery of immunomodulatory payloads to stimulate anti-tumor immunity.
Services
Provision or coordination of scalable GMP manufacturing capacity and workflows to produce clinical-grade vaccine material for off-the-shelf and personalized candidates.
Provision or coordination of scalable GMP manufacturing capacity and workflows to produce clinical-grade vaccine material for off-the-shelf and personalized candidates.
Expertise Areas
- Neoantigen-based cancer vaccine development
- Viral vector platform engineering and vectorology (adenoviral and MVA systems)
- Personalized vaccine manufacturing and rapid GMP workflows
- Preclinical immunology, tumor models and challenge studies
Key Technologies
- High-capacity adenoviral vectors
- Modified Vaccinia Ankara (MVA) vectors
- Oncolytic viral platforms
- Neoantigen prioritization algorithms (mutanome analysis)
News & Updates
Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development
Preclinical studies investigating a vaccine based on a non-human Great Apes adenovirus that encodes multiple neoantigens, capable of eradicating large tumors in mouse models when combined with checkpoint inhibitors.
Nouscom raised €42 million in Series B funding to advance its lead program NOUS-209 into Phase I/II clinical studies.
Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development
Preclinical studies investigating a vaccine based on a non-human Great Apes adenovirus that encodes multiple neoantigens, capable of eradicating large tumors in mouse models when combined with checkpoint inhibitors.
Nouscom raised €42 million in Series B funding to advance its lead program NOUS-209 into Phase I/II clinical studies.